AI
Commented by André Will-Laudien on March 28th, 2025 | 07:20 CET
Doubling possible: Using artificial intelligence! Deutsche Telekom, NetraMark Holdings, Kontron, and 1&1
Combining artificial intelligence (AI) and 5G opens up new possibilities in various areas. The strengths of 5G, such as high speed, low latency, and large network capacity, perfectly complement the capabilities of AI. The goal is to recognize complex patterns, automate processes, and make decisions in real time. AI has long since found its place in medicine and pharmaceutical development. High-tech and telecom companies are working on many promising topics here. For some stocks, this is the starting signal for a higher valuation. We highlight some of the opportunities.
Read
Commented by Fabian Lorenz on March 25th, 2025 | 07:30 CET
Stocks in RALLY MODE: Deutz, Nel ASA with momentum! MiMedia taps into huge revenue potential with Walmart!
MiMedia has huge revenue potential and a favorable valuation. The cloud insider tip offers an exciting entry opportunity in Latin America after its partnership with Walmart. After a strong price increase at the turn of the year, the share is currently moving sideways – for now. Deutz's stock has shown how quickly a share price can rise in recent weeks. However, after the approximately 40% rally, the air is getting thinner, at least when looking at the figures for 2024. However, analysts think further price gains are possible. Nel has shown signs of life. The beleaguered hydrogen pioneer has landed a new major shareholder in Samsung and recently secured a major contract. Who will continue the rally?
Read
Commented by Armin Schulz on March 25th, 2025 | 07:10 CET
Evotec, NetraMark, Novo Nordisk – From the lab to a golden digital future with artificial intelligence
The pharmaceutical industry is experiencing a revolution that is changing everything! Artificial intelligence is sweeping through laboratories and breaking with old habits. Algorithms scour billions of chemical structures in record time, uncovering hidden treasures of active ingredients. While years used to pass before a drug entered the testing phase, AI models are now picking up the pace. Heavyweights like AstraZeneca are in a neck-and-neck race with start-ups. Who will be the first to crack incurable diseases? The goal is to tailor therapies, revolutionize clinical studies, and save lives. Only those who use AI will remain competitive and be able to offer patients innovative drugs faster. The era of data-driven medicine has begun.
Read
Commented by Stefan Feulner on March 24th, 2025 | 07:00 CET
Nel ASA, Almonty Industries, Tencent – Merz and Trump as trend accelerators
The past stock market week was quite a rollercoaster. In addition to the approval of the billion-euro package by the Bundesrat and Bundestag, which helped the DAX to reach new highs at times, the activities of the old and new US President Donald Trump also caused high volatility on the global stock markets. In particular, defense stocks such as Rheinmetall, Steyr, and Deutz, as well as companies that produce the raw materials needed for rearmament, benefited and could continue their rally.
Read
Commented by Armin Schulz on March 19th, 2025 | 07:00 CET
SAP, MiMedia, Alibaba – Why Cloud Services are the Gold mines of the Future
Microsoft once again set a milestone in the second quarter of 2025 with a turnover of USD 69.6 billion. Driven by cloud services, which increased by 21%, and artificial intelligence (AI), which grew by 175%, the tech giant exceeded analysts' expectations. Azure and cloud services alone grew by 31%, while the AI business generated USD 13 billion. But the race has only just begun: Microsoft plans to spend USD 80 billion on AI data centers, which is just a fraction of the global investments that are expected to catapult the cloud market to USD 2.4 trillion by 2030. Who is footing the bill for the hunger for AI? And who stands to benefit most? The answers lie in the cloud.
Read
Commented by Fabian Lorenz on March 18th, 2025 | 07:35 CET
D-Wave and naoo stocks escalate! Will the rally continue? HelloFresh after a price slide with a 100% chance?
100% in one week! D-Wave's stock made a spectacular comeback last week. Despite stagnating revenues and high losses, investors pushed the stock to its old record level of USD 10. Can the rally continue after such a strong outlook? naoo's stock has also rebounded. The newcomer to the German stock market combines the opportunities of social media and AI. The sell-off was likely exaggerated, and a takeover caused the price to jump. And what about HelloFresh? After a disappointing outlook, the stock fell sharply. Is a 100% price gain possible now?
Read
Commented by André Will-Laudien on March 17th, 2025 | 07:20 CET
After the NASDAQ correction – Hightech on the rebound: Palantir, Amazon, MiMedia, SMCI, and Intel on the rise
The NASDAQ correction was sharp and brief, with a 15% drop from 22,200 to 19,100 in just 4 weeks. In the context of a normal consolidation, that might be enough to bring the heavily overbought tech stocks back to normal levels. Unfortunately, however, there are also valid fundamental reasons that can be traced back to the official chaos of the new US President, Donald Trump. He is making wild tariff demands and withdrawing key resources from all international partnerships. This departure from normal political behavior could have a much more significant impact on the stock market, as global trade relations are faltering, while inflation and currency devaluation continue. Which tech stocks should be considered now?
Read
Commented by Stefan Feulner on March 17th, 2025 | 07:00 CET
Palantir, NetraMark, Alibaba – AI stocks set for an upward trend
For the first time in history, the German leading index, DAX, broke through the historic 23,000-point mark in the past trading week. There were also records to report for the precious metal gold, which jumped over the USD 3,000 per ounce mark. In comparison, US indices, like the Dow Jones or Nasdaq, are still in a correction cycle. However, signs of stabilization are emerging, particularly with the Nasdaq, which may present interesting entry opportunities after the massive losses in tech stocks.
Read
Commented by Juliane Zielonka on March 13th, 2025 | 07:00 CET
Big Pharma's billion-dollar markets under pressure – NetraMark as the key for Bayer and Novo Nordisk?
In 2025, the pharmaceutical market faces significant challenges, including rising costs and regulatory hurdles. In this environment, companies like NetraMark, Bayer, and Novo Nordisk could make a significant difference through innovative solutions and strategic partnerships. NetraMark, a Canadian HealthTech company, is revolutionizing clinical trials with AI technology, which could be particularly beneficial in the areas of research into active ingredients for the central nervous system and in oncology. These are currently the biggest dropouts in industry. NetraMark's technology could increase the efficiency of drug development and open up new opportunities for investors. Bayer is focusing on targeted therapies in precision oncology and has a promising drug in development that specifically targets an overarching mutation in various cancers. Novo Nordisk is cementing its reputation as an innovator in the fight against chronic obesity, particularly with its successor to the obesity drug CagriSema. The Phase III REDEFINE 2 study achieved its primary objective, although the results fell short of high expectations. A closer look is now warranted.
Read
Commented by André Will-Laudien on March 11th, 2025 | 07:45 CET
Artificial Intelligence – Fabulous profits with Xiaomi, Credissential, D-Wave, and Palantir
It is incredible how politics can sometimes drive markets. US President Donald Trump had broken away from Ukraine aid due to a dispute with Volodymyr Zelenskyy, and the alarm bells were immediately ringing in Europe. Defense stocks went through the roof, and EU governments scrambled to come up with new special packages to rearm NATO countries, totaling up to EUR 800 billion. The flustered chaos must have amused Vladimir Putin. However, a correction is also currently taking place in the long-hyped AI stocks. Some of the losses here are quite painful. The stock market seems to have discarded its "one-way street decree". Accumulated profits should be secured as quickly as possible. We delve deeper into the context.
Read